Atreca (Atreca) Scaled Net Operating Assets : -0.08 (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Atreca Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Atreca's operating assets for the quarter that ended in Sep. 2023 was $4.95 Mil. Atreca's operating liabilities for the quarter that ended in Sep. 2023 was $14.30 Mil. Atreca's Total Assets for the quarter that ended in Jun. 2023 was $115.07 Mil. Therefore, Atreca's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2023 was -0.08.

Atreca Scaled Net Operating Assets Historical Data

The historical data trend for Atreca's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atreca Scaled Net Operating Assets Chart

Atreca Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Scaled Net Operating Assets

Get a 7-Day Free Trial

-5.74

0.12

0.01

0.14

0.36

Atreca Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.39	0.42	0.44	0.51	-0.08

Competitive Comparison of Atreca's Scaled Net Operating Assets

For the Biotechnology subindustry, Atreca's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Atreca's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atreca's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Atreca's Scaled Net Operating Assets falls into.

Atreca Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Atreca's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2022 )
=	(Operating Assets (A: Dec. 2022 )	-	Operating Liabilities (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2021 )
=	(84.535	-	12.749)	/	200.057
=	0.36

where

	Operating Assets		(A: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	155.03	-	70.495
=	84.535

	Operating Liabilities		(A: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	76.624	-	60.331	-	3.544
=	12.749

Atreca's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Sep. 2023 )
=	(Operating Assets (Q: Sep. 2023 )	-	Operating Liabilities (Q: Sep. 2023 ))	/	Total Assets (Q: Jun. 2023 )
=	(4.954	-	14.302)	/	115.069
=	-0.08

where

	Operating Assets		(Q: Sep. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	26.342	-	21.388
=	4.954

	Operating Liabilities		(Q: Sep. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	15.583	-	0	-	1.281
=	14.302

Atreca Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Atreca's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Atreca (Atreca) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atreca Inc (OTCPK:BCEL) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

0C1:Germany

Address

835 Industrial Road, Suite 400, San Carlos, CA, USA, 94070

Website

https://www.atreca.com

Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. It has single segment business of therapeutic drug discovery and development. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Executives

Felix Baker	other: Former 10% Owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	other: Former 10% Owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	other: Former 10% Owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	other: Former 10% Owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Roger Richard Ruiz	officer: VP of Finance	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Stephen E Gould	officer: Chief Scientific Officer	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Tito Serafini	director, officer: Chief Strategy Officer	C/O ATRECA, INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Phillips Courtney	officer: General Counsel & Secretary	ATRECA INC., 500 SAGINAW DRIVE, REDWOOD CITY CA 94063
Philippe C Bishop	officer: Chief Medical Officer	C/O ATRECA, INC., 835 INDUSTRIAL ROAD, SUITE 400, SAN CARLOS CA 94070
John A Orwin	director, officer: President & CEO	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Stacey Ma	director	C/O ATRECA, INC., 835 INDUSTRIAL RD., SUITE 400, SAN CARLOS CA 94070
Stephen R Brady	director	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Norman Michael Greenberg	officer: Chief Scientific Officer	500 SAGINAW DRIVE, REDWOOD CITY CA 94063
William Hewitt Robinson	director	500 SAGINAW DRIVE, REDWOOD CITY CA 94063